Morepen Laboratories · NSE: MOREPENLAB · BSE: 500288
Q3 FY25 results · Oct–Dec 2024
Morepen Laboratories reported revenue from operations of ₹452.78 crore (up 1.9% from Q3 FY24) and net profit of ₹26.69 crore (down 16.6% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 452.78 | 444.55 | +1.9% | 437.73 | +3.4% |
| Other income | 5.34 | 4.07 | +31.1% | 4.99 | +7.0% |
| Total income | 458.12 | 448.62 | +2.1% | 442.71 | +3.5% |
| Profit before tax | 35.21 | 44.02 | −20.0% | 46.02 | −23.5% |
| Net profit for the period | 26.69 | 31.99 | −16.6% | 34.85 | −23.4% |
| EPS, basic (₹) | 0.49 | 0.63 | −22.2% | 0.65 | −24.6% |
| Net margin (%) | 5.9 | 7.2 | 8.0 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 403.25 | 394.63 | +2.2% | 383.70 | +5.1% |
| Other income | 4.87 | 3.66 | +33.2% | 4.63 | +5.2% |
| Total income | 408.13 | 398.29 | +2.5% | 388.33 | +5.1% |
| Profit before tax | 30.38 | 47.22 | −35.7% | 42.86 | −29.1% |
| Net profit for the period | 22.69 | 35.20 | −35.6% | 31.93 | −28.9% |
| EPS, basic (₹) | 0.41 | 0.69 | −40.6% | 0.60 | −31.7% |
| Net margin (%) | 5.6 | 8.9 | 8.3 |
Consolidated
- Filed with BSE
- 06 Feb 2025, 18:40 IST
- Board meeting
- 06 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Feb 2025, 18:40 IST
- Board meeting
- 06 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE